A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT)

Siami, Paul; Seidman, Larry; Lama, Daniel

doi:10.1016/s0149-2918(02)85137-2

Cited by 50 publications

(34 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women under 45 years of age made up 39% and nonwhite subjects 33% of the study population; mean age was 48 years and 67% of participants were white. In previous OAB studies, mean age ranged from 56 to 63 years, and the percentage of white participants ranged from 80% to 99% [13,[20][21][22]. However, OAB and UUI are also prevalent [2] and associated with decreased HRQL [8,9] and increased rates of depression [7] in younger women.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

et al. 2008

View full text Add to dashboard Cite

We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary incontinence (UUI) treated with tolterodine extended release (ER). Sexually active women with OAB symptoms were randomized to placebo or tolterodine ER. Five-day bladder diaries, Sexual Quality of Life Questionnaire-Female (SQOL-F), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and Hospital Anxiety and Depression Scale (HAD) were completed at baseline and week 12. Tolterodine ER (n = 201; mean +/- SD age, 49 +/- 12 years) reduced UUI episodes (P = 0.0029), total (P = 0.0006) and OAB (P < 0.0001) micturitions, and pad use per 24 h (P = 0.0024), and was associated with improvements in SQOL-F (P = 0.004), PISQ total (P = 0.009), and HAD Anxiety (P = 0.03) scores versus placebo (n = 210; mean +/- SD age, 47 +/- 12 years). OAB symptoms improved with tolterodine ER as did the scores of sexual health and anxiety measures in sexually active women with OAB.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Previous OAB clinical trials have underrepresented younger women [13,[20][21][22]. In addition, there are little data on whether OAB treatment is associated with improvements in sexual health, anxiety, and depression.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Both US and European analyses have concluded that no drug is consistently more effective than another [5,7,22] and the focus here is pharmacological versus behavioral approaches, not on comparison of individual drugs. The drug treatments reviewed were extended-release tolterodine, extended-release oxybutynin, trospium, solifenacin, darifenacin, and fesoterodine; all have been studied extensively for the treatment of incontinence [13,14,[23][24][25][26][27]. Figure 1 shows the treatment pathway for FBT for illustration; the other two treatments follow the same model.…”

Section: Treatment Options and Modelsmentioning

confidence: 99%

Treating Urge Incontinence in Older Women: A Cost-Effective Investment in Quality-Adjusted Life-Years (QALY)

Phillips

Tehrani

Langmuir

et al. 2015

Journal of Geriatrics

View full text Add to dashboard Cite

Objectives. To conduct cost-effectiveness analyses of urge incontinence treatments for older women. Methods. Decision-analytic models assessed three treatment pathways: (1) limited behavioral therapy (LBT); (2) full behavioral therapy (FBT) with biofeedback; and (3) drug (DRUG), with allowances for crossover options following initial treatments. Model inputs were gathered from published data. Cost data were based on third party payer reimbursement. Outcomes were measured as the number of incontinence episodes avoided and quality-adjusted life years gained (QALYs). Results. At baseline values costs per QALY gained ranged from US$3696 to $10609. LBT was the least costly with the lowest benefit. Switching from LBT to FBT, with the greatest gain, was $415 per additional QALY. DRUG was the most expensive option. Sensitivity analyses showed that only small changes in key inputs were required for DRUG to generate greater gains than FBT. Medication costs had to fall substantially for DRUG to be cost competitive. Conclusion. All treatment strategies provide QALYs gains at a bargain price, compared to the standard of US$50,000 per QALY gained. No single treatment strategy dominated under all conditions. Clinicians should offer multiple treatment options to older women with urge incontinence.

show abstract

“…Both Trial I and Trial II are multicentre randomised controlled trials in which participants with OAB are asked to complete the OAB-q at baseline, four weeks, and twelve weeks [22]. A sub-sample of 391 patients randomly selected from the baseline analysis of Trial I are used to select items for the reduced health-state classification.…”

Section: Oab-q Datasets and Rasch Modellingmentioning

confidence: 99%

The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT)

Cited by 50 publications

References 14 publications

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

Treating Urge Incontinence in Older Women: A Cost-Effective Investment in Quality-Adjusted Life-Years (QALY)

The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis

Contact Info

Product

Resources

About